In Re Emergent Biosolutions Inc. Stockholder Derivative Litigation

Track this case

Case Number:

8:21-cv-01595

Court:

Maryland

Nature of Suit:

Stockholders Suits

Multi Party Litigation:

Derivative Litigation

Judge:

Deborah L. Boardman

Firms

Companies

Sectors & Industries:

  1. August 07, 2025

    BioPharma Co.'s $15M Deal Over Ruined J&J Vaccines OK'd

    A Maryland federal judge on Thursday granted final approval to a $15 million settlement to close out a stockholder derivative suit claiming Emergent BioSolutions Inc. and its top brass made a mint selling stock before their allegedly lax oversight led to the contamination of over 15 million Johnson & Johnson COVID-19 vaccine doses.

  2. June 30, 2021

    Pension Fund Sues BioPharma Board Over COVID Vax Fiasco

    An Illinois pension fund slapped top directors at Emergent BioSolutions Inc. with a derivative suit claiming board members made a mint selling stock before their lax oversight led to the contamination of over 15 million Johnson & Johnson COVID-19 vaccine doses.